Arbutus Biopharma Corp (ABUS) returns
Arbutus Biopharma returns over 10 years
$1,000 invested in Arbutus Biopharma ten years ago was worth $1,337 at the close on October 30, 2026, with dividends reinvested: an average return of 2.9% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -11.9% | — | $880.75 | -0.9% |
| 3 months | -4.5% | — | $954.65 | +2.1% |
| Year to date | -12.5% | — | $875.26 | +11.7% |
| 1 year | -13.0% | — | $869.84 | +12.4% |
| 3 years | +136.5% | +33.2% | $2,365 | +88.5% |
| 5 years | +4.5% | +0.9% | $1,045 | +76.0% |
| 10 years | +33.7% | +2.9% | $1,337 | +316.6% |
Arbutus Biopharma return by calendar year
| Year | ABUS | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -12.5% | +11.7% | -24.2% |
| 2025 | +47.1% | +17.7% | +29.4% |
| 2024 | +30.8% | +24.9% | +5.9% |
| 2023 | +7.3% | +26.2% | -18.9% |
| 2022 | -40.1% | -18.2% | -21.9% |
| 2021 | +9.6% | +28.7% | -19.2% |
| 2020 | +27.7% | +18.4% | +9.3% |
| 2019 | -27.4% | +31.2% | -58.6% |
| 2018 | -24.2% | -4.6% | -19.6% |
| 2017 | +106.1% | +21.7% | +84.4% |
| 2016 | -44.9% | +12.0% | -56.9% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: ABUS financials · ABUS valuation
No forecast, no recommendation. This page describes Arbutus Biopharma Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.